Radiopharm Theranostics 주식 가격. RADX - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

3.05

매수가

3.76

매도가

5.06

거래량

6,962

3.80 일간 변동폭 4.16

0.00 52주 범위 0.00

전일 종가

3.99

개장가

4.16

최근 거래 시간

3.94

마지막 거래 시간

평균 볼륨(3m)

재정 규모

US$ 27,456

VWAP

3.9436

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

RADX - Frequently Asked Questions (FAQ)

What is the current Radiopharm Theranostics share price?

The current share price of Radiopharm Theranostics is US$ 3.05

What is the 1 year trading range for Radiopharm Theranostics share price?

Radiopharm Theranostics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

가장 활성
% 상승자
% 패자

기호	가격	볼륨
DMNDamon Inc	US$ 0.0075 (97.37%)	2.97B
WWWW International Inc	US$ 0.73 (76.54%)	579.89M
OMHOhmyhome Ltd	US$ 3.10 (52.71%)	75.36M
ULYUrgent ly Inc	US$ 11.34 (51.20%)	2.24M
HPHHighest Performances Holdings Inc	US$ 12.25 (49.76%)	350.85k
PTPIPetros Pharmaceuticals Inc	US$ 0.0129 (-77.72%)	472.15M
IXHLIncannex Healthcare Ltd	US$ 0.1515 (-75.16%)	18.2M
IOTRiOThree Ltd	US$ 0.38 (-58.24%)	7.59M
ZYBTZhengye Biotechnology Holding Ltd	US$ 8.82 (-37.67%)	1.52M
NEONeoGenomics Inc	US$ 6.57 (-34.10%)	13.17M
DMNDamon Inc	US$ 0.0075 (97.37%)	2.97B
LGMKLogicMark Inc	US$ 0.01625 (25.97%)	2.82B
WWWW International Inc	US$ 0.73 (76.54%)	579.89M
PTPIPetros Pharmaceuticals Inc	US$ 0.0129 (-77.72%)	472.15M
GNLNGreenlane Holdings Inc	US$ 0.0124 (3.33%)	357.56M

81vette 2 월 전

Nice moves,zero borrow beauty

👍️0

bluebird50 2 월 전

What's going on here?

👍️0

Invest-in-America 5 월 전

RADX: Whelp, for what it's worth, here's the new RADX iHub BOARD!!!! (They make cute DIAGNOSTIC --- & potentially THERAPEUTIC, as well --- Medical gadgets that can enter tiny, obscure, sites in our Homo sapiens BODIES; and then hopefully determine what-the-heck bad things are transpiring in there, & maybe fix them to boot!!!)

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Radiopharm Theranostics Ltd (RADX)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

RADX 최신 뉴스

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RADX - Frequently Asked Questions (FAQ)

이동자

RADX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Radiopharm Theranostics Ltd (RADX) 시세

Radiopharm Theranostics Ltd (RADX)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

RADX 최신 뉴스

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RADX - Frequently Asked Questions (FAQ)

이동자

RADX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

아래의 ADVFN 계정 가입하기

광고 제거

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR